ALVO:OMXICEAlvotech Analysis

ALVO is trading at $3.46, just above its computed support of $3.19 and well below the $4.01 resistance level. The 20‑day SMA ($3.53) sits slightly above the current price, while the 50‑day SMA ($3.56) remains higher, indicating a short‑term down‑trend. Momentum is neutral, with the RSI at 47.3 and a bearish MACD histogram (-0.018) confirming lingering weakness. Volume has been decreasing, and the 30‑day volatility is an extreme 90.8%, underscoring a choppy market environment. A beta of roughly 0.82 suggests the stock moves less than the market, but the high volatility pushes the overall risk profile upward. The Fear & Greed Index reads 87.9 – “Extreme Greed” – which may be inflating demand despite weak fundamentals.
On the fundamentals side, revenue has contracted 20.2% year‑over‑year to $562 M and profit margins are negative, with operating cash flow and free cash flow both in the negative $100 M range. The balance sheet carries more than $1.45 B of debt and a negative book value per share, resulting in a troubling PB ratio of -3.83. Nevertheless, forward earnings are projected positive (forward EPS $0.23) and the forward P/E of 14.7 is well below the industry average of 28.99, implying relative undervaluation. Analysts’ target mean price of $14.6 translates to a potential upside of over 300% from today’s level, while the median target of $6 still offers a sizable upside. The company’s pipeline of biosimilar products in high‑growth therapeutic areas could drive future revenue, but regulatory approvals and cash‑flow constraints remain key hurdles. Given the lack of dividend and the negative cash generation, dividend sustainability is effectively non‑existent.